BlackRock Amends BioLife Solutions Stake, Signals Continued Passive Interest
Ticker: BLFS · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 834365
| Field | Detail |
|---|---|
| Company | Biolife Solutions Inc (BLFS) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its BioLife Solutions stake, still a passive holder.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating its ownership of BioLife Solutions Inc. common stock as of December 31, 2023. This filing, an amendment number 3, updates their previous disclosures regarding their passive investment in the electromedical and electrotherapeutic apparatus company. This matters to investors because it shows a major institutional investor's continued, albeit passive, interest in BioLife Solutions, potentially signaling confidence in the company's long-term prospects.
Why It Matters
This filing confirms BlackRock, a major institutional investor, continues to hold a significant, passive stake in BioLife Solutions, which can be a positive signal for other investors.
Risk Assessment
Risk Level: low — This is a routine amendment by a passive institutional investor and does not indicate any immediate risk or significant change in strategy.
Analyst Insight
Investors should note BlackRock's continued passive interest but recognize this filing doesn't signal an active change in investment strategy or a new bullish/bearish stance. It's a routine update.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- BioLife Solutions Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will maintain a passive investment strategy in BioLife Solutions Inc. (BlackRock Inc.) — high confidence, target: Q1 2025
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No: 3'.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.
What is the subject company of this filing?
The subject company is BioLife Solutions Inc., as indicated by 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as specified in the document.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' next to '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding BIOLIFE SOLUTIONS INC (BLFS).